Sector
PharmaceuticalsOpen
₹328.85Prev. Close
₹333.85Turnover(Lac.)
₹738.06Day's High
₹344.95Day's Low
₹328.8552 Week's High
₹377.9552 Week's Low
₹250.1Book Value
₹97.57Face Value
₹2Mkt Cap (₹ Cr.)
4,227.37P/E
59.21EPS
5.64Divi. Yield
0.361 Sep 2023
12:00 AM
BookCloser
31 Aug 2023
12:00 AM
AGM
Announcement Date: 31 Aug, 2023
2 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
8 Feb 2024
12:00 AM
Dividend
Dividend Amount: 0.6
Record Date: 20 Feb, 2024
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 24.66 | 24.66 | 24.66 | 24.66 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,108.83 | 1,043.35 | 908.76 | 791.86 |
Net Worth | 1,133.49 | 1,068.01 | 933.42 | 816.52 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 1,720.43 | 1,507.26 | 1,296.09 | 1,013.93 |
yoy growth (%) | 14.14 | 16.29 | 27.82 | 9.53 |
Raw materials | -908.37 | -776.32 | -698.97 | -509.37 |
As % of sales | 52.79 | 51.5 | 53.92 | 50.23 |
Employee costs | -164.31 | -156.56 | -128.05 | -116.69 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 206.42 | 141.98 | 111.49 | 83.22 |
Depreciation | -85.24 | -82.46 | -85.59 | -69.14 |
Tax paid | -73.28 | -42.14 | -34.26 | -12.54 |
Working capital | 48.62 | 51.62 | 54.17 | 112.99 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.14 | 16.29 | 27.82 | 9.53 |
Op profit growth | 18.2 | 12.99 | 22.58 | 8.99 |
EBIT growth | 24.8 | 21.03 | 22.14 | 13.85 |
Net profit growth | 57.68 | 9.33 | 9.27 | 71.04 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 1,768.66 | 2,004.7 | 1,926.03 | 1,707.06 | 1,462.12 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,768.66 | 2,004.7 | 1,926.03 | 1,707.06 | 1,462.12 |
Other Operating Income | 15.94 | 18.33 | 16.69 | 13.38 | 45.14 |
Other Income | 2.45 | 5.41 | 4.89 | 4.98 | 3.7 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non-Exec & Non-Independent Dir
Baba Kalyani
Executive Chairman
Jai Hiremath
Managing Director
Sameer Hiremath
Non-Exec. & Independent Dir.
Kannan Unni
Non-Exec & Non-Independent Dir
Sugandha Hiremath
Non-Exec. & Independent Dir.
Prakash V Mehta
Non-Exec & Non-Independent Dir
Amit B Kalyani
Non-Exec. & Independent Dir.
Ranjit Shahani
Non-Exec. & Independent Dir.
Shivani Bhasin Sachdeva
Company Sec. & Compli. Officer
Rajasekhar Reddy
Independent Director
Shrikrishna K. Adivarekar
Independent Director
Berjis Minoo Desai
Independent Director
V R Kaundinya
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Hikal Ltd
Summary
Hikal Limited, incorporated on July 08th, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals. The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. Presently, it is operating in the crop protection and pharmaceuticals space.The Company has 5 manufacturing facilities across three states in India. It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division. Within pharmaceutical division, it offer human health and animal health products.Hikal commenced its first project in 1991 at its first greenfield site at M.I.D.C., Mahad with the manufacture of intermediates for agrochemical industry. It also bagged first big contract with Hoechst. During 1996, Company came with public issue to part finance the expansion project of Thiabendazol. It achieved another milestone when Merck & Co., USA chose Hikal as a partner to outsource Thiabendazole (TBZ, a fungicide). Since the capacity at Mahad was inadequate, Hikal built second greenfield site, a state-of-the-art manufacturing facility at Taloja in 1997. The Company has been accorded Export House status by the Government of India. It set up a new manufactu
Read More
What is the Hikal Ltd share price today?
The Hikal Ltd shares price on N/A is Rs.₹342.65 today.
What is the Market Cap of Hikal Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hikal Ltd is ₹4224.90 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Hikal Ltd?
The PE and PB ratios of Hikal Ltd is 59.21 and 3.47 as of 22 Jul ‘24
What is the 52 Week High and Low of Hikal Ltd?
The 52-week high/low is the highest and lowest price at which a Hikal Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Hikal Ltd is ₹258.6 and ₹376.15 as of 22 Jul ‘24
What is the CAGR of Hikal Ltd?
Hikal Ltd's CAGR for 5 Years at 17.38%, 3 Years at -15.66%, 1 Year at 7.97%, 6 Month at 13.70%, 3 Month at 11.80% and 1 Month at 10.41%.
What is the shareholding pattern of Hikal Ltd?
The shareholding pattern of Hikal Ltd is as follows:
Promoters - 68.85 %
Institutions - 10.08 %
Public - 21.07 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
